Pharmadax Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 154.8 million compared to TWD 253.59 million a year ago. Net loss was TWD 167.32 million compared to TWD 125.2 million a year ago. Basic loss per share from continuing operations was TWD 2.36 compared to TWD 1.86 a year ago. Diluted loss per share from continuing operations was TWD 2.36 compared to TWD 1.86 a year ago.